Lomitapide, mipomersen, and icosapent provide novel pharmacological mechanisms for lipid-lowering therapy in patients with dyslipidemia.
May expand options for refractory dyslipidemia; leaves open need for outcome trials before guideline integration.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cassagnol et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: